{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:56:20Z","timestamp":1788350180221,"version":"build-2803163510"},"reference-count":17,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Our aim was to validate the performance of the American College of Rheumatology (ACR)\/European League Against Rheumatism (EULAR) classification criteria for antiphospholipid syndrome (APS), published in 2023, in an APS cohort. Methods: A total of 193 patients, 83 with APS (secondary APS, n = 45; primary APS, n = 38) and 110 without APS (systemic lupus erythematosus (SLE), n = 100; others, n = 10), were included in this study. The performance (sensitivity, specificity and area under the curve (AUC)) of the 2023 ACR\/EULAR classification criteria for APS was evaluated and the agreement with the revised Sapporo criteria was compared using the kappa test. Results: In our cohort, the sensitivity and specificity of the 2023 ACR\/EULAR classification criteria for APS were 73% and 94%, respectively (AUC: 0.836, 95% CI: 0.772\u20130.899), while the sensitivity and specificity of the revised Sapporo criteria were 66% and 98%, respectively (95% CI: 0.756\u20130.888). The performance of the two sets of criteria in our cohort was significantly consistent and significant (p &lt; 0.001). When the sensitivity, specificity and ROC curve analysis were performed again by excluding livedo racemosa, the sensitivity of the new criteria in our cohort was 62% and the specificity was 100% (AUC: 0.813, 95% CI: 0.746\u20130.881). Conclusions: Although the newly published criteria broaden the scope of APS classification by including clinical findings other than thrombosis and obstetric criteria, their sensitivity in our cohort was low. On the other hand, we found that the specificity of the criteria in our cohort reached 100% when livedo findings were excluded.<\/jats:p>","DOI":"10.3390\/diagnostics14192205","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T11:29:24Z","timestamp":1727868564000},"page":"2205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Validation of the 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria in a Cohort from Turkey"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-1855","authenticated-orcid":false,"given":"Salim","family":"M\u0131s\u0131rc\u0131","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-1293","authenticated-orcid":false,"given":"Ali","family":"Ekin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Ya\u011f\u0131z","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-4157","authenticated-orcid":false,"given":"Belk\u0131s Nihan","family":"Co\u015fkun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ediz","family":"Dalk\u0131l\u0131\u00e7","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/lupus-2023-001018","article-title":"Therapy with Direct Oral Anticoagulants for Secondary Prevention of Thromboembolic Events in the Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis of Randomised Trials","volume":"10","author":"Adelhelm","year":"2023","journal-title":"Lupus Sci. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109803","DOI":"10.1016\/j.clim.2023.109803","article-title":"Anti-Phospholipid Autoantibodies in Human Diseases","volume":"256","author":"Qin","year":"2023","journal-title":"Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00296-023-05457-5","article-title":"The Effects of Hydroxychloroquine and Its Promising Use in Refractory Obstetric Antiphospholipid Syndrome","volume":"44","author":"Fierro","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.22510","article-title":"Reproductive and Menopausal Factors and Risk of Systemic Lupus Erythematosus in Women","volume":"56","author":"Costenbader","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and Mortality in the Antiphospholipid Syndrome during a 10-Year Period: A Multicentre Prospective Study of 1000 Patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative Antiphospholipid Syndrome","volume":"62","author":"Hughes","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-014-0415-x","article-title":"New Tests to Detect Antiphospholipid Antibodies: Antiprothrombin (APT) and Anti-Phosphatidylserine\/Prothrombin (APS\/PT) Antibodies","volume":"16","author":"Sciascia","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: The Global Anti-Phospholipid Syndrome Score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Liu, X., Zhu, L., Liu, H., Cai, Q., Yun, Z., Sun, F., Jia, Y., Guo, J., and Li, C. (2022). Non-Criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: Diagnostic Value Added. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.972012"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/03009742.2022.2082114","article-title":"Patients with Laboratory Criteria of Anti-Phospholipid Syndrome and \u2018Non-Criteria\u2019 Manifestations: A Multicenter Cohort","volume":"52","author":"Ferreira","year":"2023","journal-title":"Scand. J. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of Antiphospholipid Syndrome: Macro- and Microvascular Manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid Syndrome: Clinical and Immunologic Manifestations and Patterns of Disease Expression in a Cohort of 1000 Patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of Patients with Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/2229-5178.164493","article-title":"Livedo Reticularis: A Review of the Literature","volume":"6","author":"Sajjan","year":"2015","journal-title":"Indian Dermatol. Online J."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/19\/2205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:35Z","timestamp":1760112575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/19\/2205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":17,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["diagnostics14192205"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14192205","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}